How HealthVerity Audiences delivered 26.9x targeting precision for a rare kidney disease campaign
A healthcare organization needed better rare-disease marketing targeting than traditional claims-based audience segments allow, since those miss significant portions of diagnosed patients. HealthVerity Audiences built segments from confirmed clinical activity rather than limited claims data and modeled proxies. The resulting campaign reached 76% more diagnosed patients than competitors, delivered the lowest cost per diagnosed patient, and achieved a 26.9x targeting multiple by grounding segments in verified clinical signals instead of proxies.
The customer is anonymised in HealthVerity’s own case study — not withheld by us.
HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by HealthVerity on its own site — read the original case study on info.healthverity.com ↗
Related use cases
- 01Symphony Health and dentsu health partner to efficiently reach rare disease patients
- 02Differentiating TYK2 inhibitors with real-world evidence in psoriasis
- 03Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study
- 04Accurately targeting chronic liver disease patients for specialty therapy
- 05Accurately reaching patients with rare hematologic disease
- 06Accelerating early RWE exploration without increasing analytic burden